| Literature DB >> 35733068 |
Masoumeh Kiani-Zadeh1, Mohammad Reza Rezvany1,2,3, Soodeh Namjoo1,4, Mahmood Barati5, Mohammad Hossein Mohammadi6, Bahare Ghasemi1, Tahere Tabatabaei1, Ardeshir Ghavamzadeh7, Farhad Zaker8,9,10, Ladan Teimoori-Toolabi11.
Abstract
Hereby, we aimed to investigate the expression of prostaglandin-endoperoxide synthase 2 (PTGS2) and Vascular Endothelial Factor-C (VEGF-C) besides the methylation of PTGS2 in AML patients. VEGF-C and PTGS2 expression analysis were evaluated in newly diagnosed AML patients and healthy controls by quantitative Reverse Transcriptase PCR method. Also, PTGS2 methylation status was evaluated by Methylation-Sensitive High-Resolution Melting Curve Analysis (MS-HRM). While 34% of patients were female, the mean age of the patients was 43.41 ± 17.60 years suffering mostly from M4 (48.21%) type of AML. Although methylation level between patients and controls was not significantly different, none of the normal controls showed methylation in the PTGS2 promoter. PTGS2 and VEGF-C levels were elevated in AML cases and correlated with WBC, Platelet, and Hemoglobin levels. The survival of patients with overexpressed VEGF-C and PTGS2 was poorer than others. It can be concluded that PTGS2 and especially VEGF-C expression but not PTGS2 methylation can be considered as diagnostic biomarkers for AML.Entities:
Keywords: DNA methylation; Gene expression; Leukemia, myeloid, acute; PTGS2 protein, human; Real-time polymerase chain reaction; Vascular endothelial growth factor C
Mesh：
Substances：
Year: 2022 PMID： 35733068 DOI： 10.1007/s11033-022-07615-7
Source DB: PubMed Journal: Mol Biol Rep ISSN： 0301-4851 Impact factor: 2.742